MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Начало・Списък с акции・Theravance Biopharma Inc

Theravance Biopharma Inc

Затворен

8.44 -3.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.31

Максимум

8.73

Ключови измерители
By Trading Economics
Приходи	-2.8M -16M
Продажби	1.9M 19M
EPS	-0.05
Марж на печалбата	-82.793
Служители	97
EBITDA	1.1M -7.6M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+40.59% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	3.4M 456M
Предишно отваряне	11.76
Предишно затваряне	8.44

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

N/A / 9.32 Подкрепа & съпротива

Theravance Biopharma Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.04.2025 г., 22:38 ч. UTC

Горещи акции

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

4.04.2025 г., 21:53 ч. UTC

Пазарно говорене

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4.04.2025 г., 21:44 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4.04.2025 г., 21:00 ч. UTC

Топ новини

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4.04.2025 г., 20:52 ч. UTC

Пазарно говорене

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4.04.2025 г., 20:52 ч. UTC

Топ новини

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4.04.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.04.2025 г., 20:48 ч. UTC

Топ новини

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4.04.2025 г., 20:45 ч. UTC

Топ новини

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4.04.2025 г., 20:32 ч. UTC

Топ новини

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4.04.2025 г., 20:21 ч. UTC

Топ новини

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4.04.2025 г., 20:00 ч. UTC

Топ новини

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4.04.2025 г., 19:51 ч. UTC

Пазарно говорене

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4.04.2025 г., 19:37 ч. UTC

Топ новини

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4.04.2025 г., 19:32 ч. UTC

Пазарно говорене

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4.04.2025 г., 19:28 ч. UTC

Топ новини

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4.04.2025 г., 19:15 ч. UTC

Пазарно говорене

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4.04.2025 г., 19:12 ч. UTC

Топ новини

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4.04.2025 г., 19:11 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4.04.2025 г., 19:09 ч. UTC

Пазарно говорене

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4.04.2025 г., 19:09 ч. UTC

Топ новини

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4.04.2025 г., 19:00 ч. UTC

Пазарно говорене

Fed Has Limited Options to Counter Tariffs -- Market Talk

4.04.2025 г., 18:53 ч. UTC

Пазарно говорене

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4.04.2025 г., 18:51 ч. UTC

Пазарно говорене

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.04.2025 г., 18:44 ч. UTC

Пазарно говорене

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

4.04.2025 г., 18:43 ч. UTC

Придобивния, сливания и поглъщания

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

4.04.2025 г., 18:43 ч. UTC

Придобивния, сливания и поглъщания

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

4.04.2025 г., 18:39 ч. UTC

Пазарно говорене

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Theravance Biopharma Inc Прогноза

Ценова цел

By TipRanks

40.59% нагоре

12-месечна прогноза

Среден 12.33 USD 40.59%

Висок 15 USD

Нисък 10 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Theravance Biopharma Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Theravance Biopharma Inc през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 9.32Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.